Resumen

PEREZ, Leslie et al. Safety of Racotumomab in the treatment of patients with non-small cell lung cancer . Vaccimonitor [online]. 2013, vol.22, n.1, pp. 10-14. ISSN 1025-028X.

In Cuba, lung cancer ranks second in incidence and first in mortality. Therefore, it is necessary to identify new therapeutical options. Immunological approaches are interesting because of the potential activity without the toxicities of conventional chemotherapy. The Center of Molecular Immunology developed a vaccine called Racotumomab; it acts on the lung carcinoma inducing an increase in tumor apoptosis and a decrease in the number of tumor vessels. A expanded access, multicenter, open study was conducted in 86 patients with non-small cell lung cancer in order to assess its safety. The administered dose was 1 mg/mL intradermically. The first 5 doses were administered every 14 days and the remaining 10 every 28 days until completing the treatment. The follow-up re immunizations were every 28 days. The occurrence of adverse events (AE) was analyzed and they were classified according to CTC v4.02 criteria. Adverse events were reported by 58 patients (67.4%), making a total of 215 events. burning at the injection site was the most frequently reported event, 32 (14.9%). The use of the vaccine in the patients under study showed good safety and tolerance.

Palabras clave : Racotumomab; clinical trial; non-small cell lung cancer; adverse events.

        · resumen en Español     · texto en Español     · Español ( pdf )